Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial: clinical studies

Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival.

Saved in:

Bibliographic Details
Main Authors:	Joensuu, Heikki (Author) , Reichardt, Annette (Author) , Eriksson, Mikael (Author) , Hohenberger, Peter (Author) , Boye, Kjetil (Author) , Cameron, Silke (Author) , Lindner, Lars H. (Author) , Jost, Philipp J. (Author) , Bauer, Sebastian (Author) , Schütte, Jochen (Author) , Lindskog, Stefan (Author) , Kallio, Raija (Author) , Jaakkola, Panu M. (Author) , Goplen, Dorota (Author) , Wardelmann, Eva (Author) , Reichardt, Peter (Author)
Format:	Article (Journal)
Language:	English
Published:	11 June 2024
In:	British journal of cancer Year: 2024, Volume: 131, Issue: 2, Pages: 299-304
ISSN:	1532-1827
DOI:	10.1038/s41416-024-02738-z
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41416-024-02738-z Verlag, kostenfrei, Volltext: http://www.nature.com/articles/s41416-024-02738-z
Author Notes:	Heikki Joensuu, Annette Reichardt, Mikael Eriksson, Peter Hohenberger, Kjetil Boye, Silke Cameron, Lars H. Lindner, Philipp J. Jost, Sebastian Bauer, Jochen Schütte, Stefan Lindskog, Raija Kallio, Panu M. Jaakkola, Dorota Goplen, Eva Wardelmann, and Peter Reichardt

Description
Summary:	Patients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival.
Item Description:	Online veröffentlicht: 11. Juni 2024 Gesehen am 25.11.2024
Physical Description:	Online Resource
ISSN:	1532-1827
DOI:	10.1038/s41416-024-02738-z